entertainment -WSS

entertainment

author：comprehensive 2025-10-01 15:29:08 - browse：2

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： In the gardens at Boston Children's Hospital, families find sanctuary

WSS

ActiGraph execs on goal of drug approvals with digital endpoints

The battle over 'scope creep' and who gets to be called 'doctor'

New details revealed about Purdue's marketing of OxyContin

Clinical trials must include more disabled people

Search called off for baby washed away in Pennsylvania flash flood

Truvian presents data for its desktop blood

knowledge

entertainment

Wikipedia

New air purifier tech could be key to improving indoor air quality

Why patients can’t get everything they want on drug pricing

Apple is now the first public company to be valued at $3 trillion

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Duchenne breakthrough therapy leaves behind pioneering families

ActiGraph execs on goal of drug approvals with digital endpoints

Medical leaders decry Supreme Court decision on affirmative action

In the gardens at Boston Children's Hospital, families find sanctuary

Dobbs anniversary: the lost opportunity of abortion as health care

Liz Cheney makes 1st public comment since Trump's election interference indictments

Wikipedia

As Maui death toll rises, number of missing remains unclear

Rise in cancer among younger people worries and puzzles doctors

What to watch for from Zogenix and Amicus clinical trials

Truvian presents data for its desktop blood

New lawsuit accuses health insurer Cigna of denying claims in bulk

Why patients can’t get everything they want on drug pricing

explore

hotspot

focus

focus